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Abstract
Objectives
Proton pump inhibitors (PPIs) are commonly prescribed for prevention and treatment of gas-
trointestinal conditions or for gastroprotection from other drugs. Research suggests they are
linked to increased dementia risk. We use linked national health data to examine the associ-
ation between PPI use and the development of incident dementia.
Methods and findings
A population-based study using electronic health-data from the Secure Anonymised Infor-
mation Linkage (SAIL) Databank, Wales (UK) from 1999 to 2015. Of data available on
3,765,744 individuals, a cohort who had ever been prescribed a PPI was developed (n =
183,968) for people aged 55 years and over and compared to non-PPI exposed individuals
(131,110). Those with prior dementia, mild-cognitive-impairment or delirium codes were
excluded. Confounding factors included comorbidities and/or drugs associated with them.
Comorbidities might include head injury and some examples of medications include antide-
pressants, antiplatelets and anticoagulants. These commonly prescribed drugs were inves-
tigated as it was not feasible to explore all drugs in this study. The main outcome was a
diagnosis of incident dementia. Cox proportional hazard regression modelling was used to
calculate the Hazard ratio (HR) of developing dementia in PPI-exposed compared to unex-
posed individuals while controlling for potential confounders.
The mean age of the PPI exposed individuals was 69.9 years and 39.8% male while the
mean age of the unexposed individuals was 72.1 years and 41.1% male. The rate of PPI
usage was 58.4% (183,968) and incident dementia rate was 11.8% (37,148/315,078). PPI
use was associated with decreased dementia risk (HR: 0.67, 95% CI: 0.65 to 0.67, p<0.01).
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Conclusions
This study, using large-scale, multi-centre health-data was unable to confirm an association
between PPI use and increased dementia risk. Previously reported links may be associated
with confounders of people using PPI’s, such as increased risk of cardiovascular disease
and/or depression and their associated medications which may be responsible for any
increased risk of developing dementia.
Introduction
Proton pump inhibitors (PPIs) have revolutionised the management of stomach acid suppres-
sion, successfully managing patients with gastro-oesophageal reflux disease (GORD). They
effectively resolve GORD symptoms in 60–80% of patients within 1–2 months [1] and their
use is on the rise [2, 3]. Long-term PPI use may also be a prophylactic measure and serve as a
gastro-protectant for concomitant medications such as aspirin, well known to irritate the
digestive tract [4, 5].
However, evidence suggests that PPIs are overprescribed [6] and inappropriately prescribed
[7, 8]. With increased prescription, particularly through Europe [9]; their cost to the National
Health Service in the UK is more than £100 million each year [10].
Some of the safety concerns associated with long-term use of PPIs include: cancer [11, 12]
masking symptoms of other underlying conditions [13], infections [14–18], celiac disease [19],
vitamin-B12 deficiency [20], abnormal kidney function [21, 22], and more recently, dementia
[23, 24]. The association between PPI and dementia is potentially mediated by a PPI-induced
increase of the protein amyloid-beta that contributes to the pathophysiology of dementia [25,
26], or vitamin-B12 deficiency caused by malabsorption induced by PPIs [27].
It was recently reported that PPI medications were associated with an almost two-fold
(44%) increased risk of developing dementia [23], causing wide-spread concern over their
safety. The findings were highlighted by the media with little mention of methodological limi-
tations. These limitations include: the study design with a selected population sourced from
German health insurance data claims; a control group with significant differences from the
PPI exposed group; and increased comorbidities. Comorbidities such as ischaemic heart dis-
ease and depression are risk factors for developing dementia. These could result in residual
confounding, contributing to an increased incidence of dementia in PPI exposed individuals
in previous studies [23]. A subsequent study, using German primary care data found that PPIs
were actually associated with a decreased risk of dementia [28]. However, a meta-analysis pub-
lished in 2016 showed an increase risk of dementia with PPI use, but only four observational
studies could be included and heterogeneity and methodological shortcomings were
highlighted [29].
Another study suggested that PPIs do not increase the risk of dementia or cognitive
impairment and were associated with an approximate 20% risk reduction. This investigation
relied on self-reporting of PPI use, which may result in misclassification and recall bias, espe-
cially if individuals had memory issues [30]. Other studies were also unable to find an associa-
tion of PPI usage and cognitive impairment or dementia [31–34] including a case-control
study which took the PPI duration of exposure in to account [35].
There are clearly challenges in evaluating the safety of PPIs [36] with studies reporting con-
tradictory findings of an increased risk of dementia [23, 24, 29] or no associated risk [28, 30–
32, 35].
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We examine a vast source of linked, routinely collected health-data while correcting for
known confounders to examine the relationship between PPI and dementia risk. We used a
cohort study so that we could directly compare our findings to existing publications.
Methods
Routinely collected data
Data were obtained from the Secure Anonymised Information Linkage (SAIL) databank [37,
38] that allows the linkage of routine clinical records. These include primary care and mortal-
ity data collected by the Office of National Statistics (ONS). The SAIL databank houses multi-
sourced records from 5 million of the living and deceased population of Wales. The records
are anonymised using a split-file approach; the demographic and clinical data are divided and
sent to a third party where a unique linking field is applied—removing any identifiers. This
allows the files to be recombined later. We are then able to, retrospectively and prospectively,
follow-up individuals anonymously through different data sources. Previous work using the
SAIL databank to investigate PPIs has been published elsewhere [39].
Primary care data is captured using Read codes relating to diagnoses, medication and pro-
cess-of-care codes [40]. The Office of National Statistics (ONS) Mortality dataset contains
demographic, place and underlying cause of death data using the International Classification
of Diseases (ICD) clinical coding system.
Data was included from December 1999 to September 2015 for optimum data coverage
purposes at the time of analysis.
Individuals who had ever taken PPIs were those with Read code records for prescriptions of
PPI medications. They were followed-up and compared to non-PPI exposed individuals. The
individuals first PPI prescription date formed the index date for the PPI exposed group. A ran-
dom index date within the follow-up period was used for the control population who did not
receive a PPI. This avoided pre-selecting a period of known ill-health for controls. In addition,
using a true event date could bias the control population to more active healthcare users, due
to their visitation to the doctor and may be less generalisable as a result. Individuals of 55 years
age or above were included due to the increased risk of gastrointestinal complaints with
advancing age [41].
Of the 3,765,744 individuals in the SAIL databank who were aged 55 years or older,
1,043,040 had records of PPI use compared to 2,722,704 who did not. Individuals were
excluded when they had less than one year of data available in their records from the index
date and/or had records of dementia, mild cognitive impairment or delirium prior to the
index date (Fig 1).
Primary outcome
The primary outcome was dementia Read codes present in the primary care data post index
date. The list of codes used for dementia classification is available in S1 Table of S1 File. These
codes have been previously validated for use in UK epidemiological studies [42]. Data was
linked to ONS data to obtain mortality data.
Covariates of interest and confounding factors
The covariates were extracted at baseline from routine primary care data using the READ
Code clinical coding system or derived data where appropriate. These included personal char-
acteristics (age, sex, smoking status, obesity and alcohol consumption). The confounding
comorbidities (diabetes, cardiovascular disease, depression, anxiety, head injury, hypertension,
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high cholesterol, vitamin-B12 deficiency and anaemia) and concomitant medications (anxio-
lytics, anti-depressants, anticoagulants, antiplatelets, statins, hormone replacement therapy
(HRT), vitamin-B12 supplements, iron and antihypertensives) were extracted throughout the
patient record; prior to or post- index date (S2 Table of S1 File). The rationale to include these
confounders during the study period was to adjust for known factors that may occur in the
long follow-up period. For instance, an extreme event such as a head injury or a long-term
health condition, such as cardiovascular disease, which may occur in either PPI exposed or
non-exposed group post-index date and these have been adjusted for in the model.
Statistical analysis
Descriptive statistics were used to examine age, gender and covariate distribution for the par-
ticipants of the cohort.
A step-wise cox proportional hazard regression model was employed to calculate hazard
ratios while controlling for covariates and potential confounding factors. Univariate analysis
(S3 Table of S1 File) determined factors to be included in the multivariate model. Censoring
occurred when a patient died, was lost to follow-up (i.e. moved out of Wales resulting in
incomplete health-records) or reaching the end of the study period (records up to 2015 at time
of analysis).
Sensitivity analysis was performed, excluding patients who were taking vitamin-B12 which
may help prevent cognitive decline [43].
Fig 1. Cohort dataset creation diagram.
https://doi.org/10.1371/journal.pone.0237676.g001
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Additionally, associations of developing dementia and the duration from first treatment
with PPI were assessed in a sensitivity analysis comprising individuals who developed demen-
tia within 2 to 4 years, 5 years to 9 years and 10 years post- index date compared to those who
had not received PPIs.
Missing data were treated as missing throughout the study. All statistical analyses were con-
ducted using STATA15.
Ethical approval
Data held in the SAIL databank are anonymised and therefore, no ethical approval is required.
All data contained in SAIL has the permission from the relevant Caldicott Guardian or Data
Protection Officer. SAIL-related projects are required to obtain Information Governance
Review Panel (IGRP) approval.
Results
Patient characteristics
The population consisted of 315,078 individuals, 40.3% were male (127184/315078) and the
mean age was 70.8 years. The mean follow-up time for the whole cohort was 13.04 years (SD:
4.95). The proportion of PPI usage was 58.4% (183,968) and the incident dementia was 11.8%
(37,148/315,078).
The PPI exposed group was slightly younger on average by 2.2 years. The proportion of
females was slightly higher in the PPI exposed group (60.2%) compared to the unexposed
group (58.9%) (Table 1).
Within the PPI exposed group, the incidence of dementia was 11.4% (21,023) and 12.3%
(16,125) for the unexposed. The mean age at dementia diagnosis was similar in the PPI and
non-PPI exposed groups; 82.1 years and 81.5 years, respectively (Table 1).
The mean follow-up time for PPI and non-PPI exposed was 10.9 years (SD: 4.0) and 8.6
years (SD: 4.4), respectively. The rate of death was significantly higher in the non-PPI (53.3%)
exposed group compared to the PPI exposed group (43.5%) (Difference: 9.8, 95% CI: 9.5 to
10.2). The age of death was similar for both groups however the PPI group was slightly older
(PPI: 85 years and non-PPI: 84.3 years) (Table 1).
The characteristics of the study populations are presented in Table 1 and S3 Table of S1
File.
PPI and dementia
PPIs were not associated with an increased risk of dementia. Rather, PPI usage was associated
with around a 30% reduced risk (Adjusted HR: 0.67, 95% CI: 0.65 to 0.69, p<0.001) (Tables 2
and 3); (Crude HR: 0.82, 95% CI: 0.80 to 0.84) (S3 Table of S1 File).
Sensitivity analysis
A sensitivity analysis of removing vitamin B-12 deficiency from the model did not alter the
results for the cohort study (S4 Table of S1 File).
To test the assumption that PPI initiation may predispose individuals to dementia, in a sen-
sitivity analysis we investigated subgroups of individuals who were diagnosed with dementia
following 2 to 4 years, 5 to 9 years and 10 years or more of first mention of PPI treatment. This
demonstrated that when excluding individuals with varying exposures to PPIs, the hazard
ratio of developing dementia reduced in the PPI exposed patients compared to the non-
exposed and furthermore, as the time period increased (Table 3).
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Discussion
This study does not find evidence that PPI use is associated with an increased risk of dementia.
Rather, in support for Booker et al., and Goldstein et al., our study, using large-scale, multi-
sourced health-data, found that PPI usage was associated with a 30% lower risk of dementia.
Our findings originate from data collected in a real-world setting which provided a heteroge-
neous sample, thereby overcoming selection bias which may have been an issue in previous
studies.
The PPI exposed and non-exposed groups were slightly different. Those who were not
treated with PPIs tended to be slightly older, smoked more and had less comorbidities and
concomitant medications recorded in their routine health records compared to the PPI
exposed group. There was also higher rate of death in the non-PPI exposed group compared to
the PPI exposed. This may suggest that patients who are treated with PPIs are more closely
monitored and are higher healthcare resource users; whereas patients who do not receive PPIs
may visit their GP less overall.
Table 1. Characteristics of PPI exposed and unexposed patients at baseline.
PPI No PPI Difference
n = 183,968 n = 131,110 (95% CI)
Age^, mean years (SD) 69.9 (70) 72.1 (7.6) 2.2 (1.8 to 2.6)
Female, % (n) 60.2% (110,720) 58.9% (77,174) 1.3 (1.0 to 1.7)
BMI^, mean (SD) 26.3 (5.1) 25.8 (5.1) 0.5 (0.5 to 0.5)
Drink alcohol^, % (n) 3% (5,510) 2.3% (2,977) 0.7 (0.6 to 0.8)
Smoker† % (n) 20.4% (36,320) 29.9% (37,290) 9.5 (9.2 to 9.8)
Dementia % (n) 11.4% (21,023) 12.3% (16,125) 0.9 (0.6 to 1.1)
Age at dementia diagnosis, mean years (SD) 82.1 (6.7) 81.5 (6.8) 0.6 (0.5 to 0.7)
Diabetes† % (n) 19.4% (35,778) 14.6% (19,132) 4.8 (4.6 to 5.1)
Cardiovascular disease† % (n) 53.9% (99,065) 38% (49,768) 15.9 (15.5 to 16.2)
Depression† % (n) 32.7% (60,167) 20.1% (26,404) 12.6 (12.3 to 12.9)
Head injury† % (n) 6.4% (11,739) 4.8% (6,315) 1.6 (1.4 to 1.7)
Vitamin B12 deficiency
† % (n) 0.8% (1,516) 0.6% (734) 0.2 (0.2 to 0.3)
Anaemia† % (n) 19.1% (35,153) 9.7% (12,739) 9.4 (9.2 to 9.6)
Anxiolytics† % (n) 29.1% (53,434) 16.8% (22,044) 12.3 (11.9 to 12.5)
Antidepressants† % (n) 50.1% (92,235) 28.9% (37,847) 21.2 (20.9 to 21.6)
Anticoagulants† % (n) 20.7% (38,002) 14.7% (19,257) 6 (5.7 to 6.2)
Antiplatelets† % (n) 66.7% (122,632) 47.2% (61,838) 19.5 (19.2 to 19.8)
Statins †% (n) 59.5% (109,444) 36.9% (48,343) 22.6 (22.3 to 23)
Hormone replacement therapy† % (n) 9.9% (18,274) 4.3% (5,617) 5.6 (5.5 to 5.8)
Vitamin B12 medication
† % (n) 5.7% (10,421) 3.4% (4,506) 2.3 (2.1 to 2.4)
Anaemia medication† % (n) 38.6% (71,047) 19% (24,933) 19.6 (19.3 to 19.9)
Antihypertensives† % (n) 71.6% (131,740) 54.1% (70,925) 17.5 (17.2 to 17.9)
H2-receptor antagonists
† % (n) 19.1% (35,203) 6.1% (7,935) 13 (12.9 to 13)
Died % (n) 43.5% (79,974) 53.3% (69,917) 9.8 (9.5 to 10.2)
Mean age died, years (SD) 85 (6.0) 84.3 (5.8) 0.7 (0.6 to 0.8)
^ Covariates collected at index date.
† Covariates collected throughout patient history, pre- or post- index date.
Missing data for PPI exposed: 36.7% for BMI (n = 67,569) and 3.3% (n = 6,057) for smoking status.
Missing data for non-exposed: 47.4% for BMI (n = 62,118) and 4.9% (n = 6,444) for smoking status.
https://doi.org/10.1371/journal.pone.0237676.t001
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When adjusted for covariates, some were associated with an increased risk of dementia (e.g.
increasing age, head injury and depression). Other factors were associated with a reduced risk
of dementia, including a lower BMI and cardiovascular disease. However, cardiovascular dis-
ease is an established risk factor for developing dementia [44]. Our findings may be explained
by the increased risk of death in those who have serious comorbidities, meaning that they are
at greater risk of dying earlier, before getting dementia.
However, some findings were interesting, for instance anticoagulants were associated with
a lower risk of dementia in this study, while those taking antiplatelets developed dementia
much earlier. However, this must be explored in additional study since this study was designed
to explore risk of dementia with PPI usage.
It is important to consider that it is not known how long dementia takes to develop and
how long the latent stages may last. Dementia may also not be diagnosed until later stages in
the disease or on the other hand, may remain undiagnosed [45–47].
Therefore, by conducting sensitivity analysis omitting patients who were recently diagnosed
with dementia following PPI treatment we could help to address the effects of misclassification
bias. For instance, those who were diagnosed with dementia within one year of PPI treatment
initiation would have been experiencing the early symptoms of dementia for some time
already. These were existing dementia cases who would have been administered PPIs during
the prodromal stage and so were misclassified. Patients who were diagnosed with dementia at
5 years and 10 years post-treatment initiation intervals also demonstrated an association of
reduced incidence in dementia adding further support to the notion that PPIs are not associ-
ated with developing dementia. However, competing interest of death may also be an
Table 2. Adjusted Hazard ratio of developing dementia when taking a PPI compared to a control population
using a retrospective cohort.
Hazard ratio 95% CI
PPI 0.67 0.65 to 0.69�
Adjusted for:
Age 1.06 1.05 to 1.06�
Smoker 0.89 0.85 to 0.92�
BMI 0.95 0.95 to 0.95�
Diabetes 1.18 1.14 to 1.22�
Cardiovascular disease 0.93 0.90 to 0.97�
Depression 1.19 1.16 to 1.23�
Head injury 1.50 1.43 to 1.56�
Vitamin-B12 Deficiency 1.37 1.21 to 1.56
�
Anxiolytics 1.62 1.57 to 1.67�
Antidepressants 1.66 1.61 to 1.72�
Anticoagulants 0.87 0.84 to 0.89�
Antiplatelets 1.72 1.66 to 1.79�
Statins 0.86 0.85 to 0.94�
Hormone replacement therapy 0.89 0.85 to 0.94�
Vitamin-B12 Medication 1.41 1.34 to 1.48
�
Anaemia Medication 1.10 1.06 to 1.13�
Antihypertensives 0.71 0.69 to 0.74�
Histamine Receptor-2 Medication 0.89 0.85 to 0.94�
�P< 0.05.
Gender, Anaemia and alcohol use were included in the model, but removed as did not reach statistical significance.
https://doi.org/10.1371/journal.pone.0237676.t002
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implication, which is often an issue with ageing cohorts. Nevertheless, no increased risk of
dementia was associated with PPI usage in this study.
Strengths
To our knowledge, this study involves the analysis of the largest-to-date follow-up of PPI and
dementia cases from routinely collected health-records with up to 16 years average follow-up
time. This allowed the assessment in a real-life setting which helps avoid selection bias and
improve generalisability. Using routinely collected health-records for research purposes means
that events are captured as they occur in the patient record rather than self-reported. There-
fore, co-conditions, medications and head injuries for instance are confirmed in the data
which overcomes recall bias in self-reported studies.
The use of a cohort study is also advantageous over a case-control design when using retro-
spective database studies, where all exposure and covariate data is already available. A case-
control approach may result in inappropriate comparisons between exposure groups and lead
to confounding [48]. Dementia can be a very slow developing condition however the long fol-
low-up in this study meant that prodromal dementia could be followed until diagnosis.
Table 3. Sensitivity analysis: Adjusted hazard ratios of developing dementia for varying time points following PPI Index date compared to unexposed controls.
Whole cohort
Including all dementia cases
(n = 37,148)
Including dementia cases
(n = 13,484) diagnosed 2 to 5
years post-index date
Including dementia cases
(n = 9,822) diagnosed 5–9
years post-index date
Including dementia cases
(n = 4,594) diagnosed 10
years or more post-index
date
36% of all dementia cases 26.4% of all dementia cases 12.4% of all dementia cases
HR 95% CI HR 95% CI HR 95% CI HR 95% CI
PPI 0.67 0.65 to 0.69� 0.58 0.56 to 0.60� 0.46 0.46 to 0.48� 0.29 0.28 to 0.30�
Age 1.05 1.05 to 1.06� 1.05 1.05 to 1.06� 1.06 1.05 to 1.06� 1.06 1.06 to 1.06�
Drink alcohol 1.10 1.01 to 1.18� 1.20 1.13 to 1.28� 1.18 1.10 to 1.25� 1.15 1.07 to 1.24�
Smoker 0.89 0.85 to 0.92� 0.89 0.86 to 0.92� 0.90 0.87 to 0.94� 0.91 0.87 to 0.95�
BMI 0.95 0.95 to 0.95� 0.95 0.95 to 0.95� 0.95 0.95 to 0.95� 0.95 0.95 to 0.95�
Diabetes 1.18 1.14 to 1.22� 1.18 1.14 to 1.23� 1.18 1.14 to 1.22� 1.18 1.13 to 1.23�
Cardiovascular disease 0.93 0.90 to 0.97� 0.94 0.91 to 0.98� 0.95 0.92 to 0.98� 0.95 0.92 to 0.99�
Depression 1.19 1.16 to 1.23� 1.19 1.15 to 1.24� 1.20 1.15 to 1.24� 1.17 1.12 to 1.21�
Head injury 1.49 1.43 to 1.56� 1.50 1.43 to 1.57� 1.51 1.43 to 1.59� 1.53 1.44 to 1.62�
Vitamin-B12 Deficiency 1.37 1.21 to 1.56
� 1.42 1.25 to 1.61� 1.41 1.23 to 1.62� 1.44 1.23 to 1.69�
Anxiolytics 1.62 1.57 to 1.67� 1.65 1.60 to 1.70� 1.69 1.63 to 1.74� 1.77 1.70 to 1.84�
Antidepressants 1.66 1.61 to 1.72� 1.68 1.62 to 1.74� 1.68 1.61 to 1.74� 1.70 1.63 to 1.78�
Anticoagulants 0.87 0.84 to 0.91� 0.88 0.85 to 0.92� 0.88 0.84 to 0.92� 0.89 0.84 to 0.93�
Antiplatelets 1.72 1.66 to 1.79� 1.72 1.66 to 1.79� 1.73 1.66 to 1.80� 1.70 1.63 to 1.78�
Statins 0.86 0.83 to 0.89� 0.86 0.83 to 0.94� 0.87 0.83 to 0.90� 0.85 0.82 to 0.89�
Hormone replacement therapy 0.89 0.83 to 0.89� 0.89 0.84 to 0.94� 0.91 0.86 to 0.96� 0.96 0.90 to 1.02
Vitamin-B12 Medication 1.37 1.34 to 1.48
� 1.44 1.37 to 1.52� 1.44 1.36 to 1.53� 1.46 1.36 to 1.56�
Anaemia Medication 1.09 1.06 to 1.13� 1.10 1.07 to 1.14� 1.11 1.07 to 1.15� 1.12 1.07 to 1.16�
Antihypertensives 0.71 0.69 to 0.73� 0.71 0.69 to 0.74� 0.71 0.68 to 0.73� 0.69 0.66 to 0.72�
Histamine Receptor-2 Medication 0.91 0.88 to 0.95� 0.97 0.93 to 1.01 1.04 1.0 to 1.09� 1.01 1.03 to 1.06�
�P < 0.05.
9,248 (24.9%) dementia cases were removed from this analysis as they developed dementia within two years of the PPI date. Gender, Anaemia and alcohol use were
included in the model, but removed as did not reach statistical significance.
https://doi.org/10.1371/journal.pone.0237676.t003
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Dementia is also a complex, multifactorial condition and known potential confounders have
been included in our analysis to help to reduce residual confounding, however this can never
be assumed to be complete.
Weaknesses
While routinely collected health-records are advantageous in their use for secondary research
purposes, they may also have their disadvantages, such as missing data. This study does not
take in to account the duration or dose of PPI treatment, however this has been investigated
elsewhere and long-term use was not associated with an increased risk of developing AD [35].
Also, some PPIs are also available to purchase over-the-counter and so, we are unable to con-
trol for this within this study. Furthermore, a prescription for PPIs in the primary healthcare
record does not necessarily guarantee that the individual has taken the medication which can
lead to misclassification bias.
Pre-symptomatic dementia cases may also have been misclassified to the control population
however this may be addressed by the time-lag sensitivity analysis.
We did not stratify on dementia type so that our findings were comparable to previous
studies [23, 24, 28]. However, our future work will explore risk factors of developing dementia
by dementia sub-type.
Given the advancing age of the cohort, the competing risk of death [49] is likely to be high
which was not controlled for in this study. The rate of death was higher in the PPI unexposed
group, however the age of death was similar for both groups and was beyond the mean age of
dementia diagnosis. A weakness of the cox proportional hazard is that the risk of disease may
be overestimated by failing to control for competing risk of death [49, 50]. As such, the hazard
ratio may be slightly over-estimated, which in this instance, adds further support to the lack of
association of PPI treatment with dementia in this cohort.
Finally, the rate of alcohol use was considerably low in the routine data. This may suggest
that the rate of reporting alcohol was indeed low, had not been recorded well in primary care or
be associated with the fact that the cohort was older and rate of drinking alcohol was truly low.
To conclude, our evidence suggests that PPIs are not associated with an increased risk of
dementia. Rather, there is a 30% reduced risk associated with the widely prescribed gastro-pro-
tectants. Mechanisms behind potential protective effects of PPIs include anti-neurotoxic
effects, such as reduction of brain oxidative stress and reduced neutrophil infiltration or
inflammation in the brain [51, 52].
Further research in to the relationship between PPIs and a reduced risk of dementia, such
as stratifying on the type of dementia can help us understand more about PPIs and their inter-
actions during the pathogenesis of distinct dementias. Medications associated with a lower
risk of dementia can be explored further, with regard to dose and duration of treatment for dif-
ferent dementias. Enhanced understanding of the associations between different medications
and dementia not only supports greater understanding of the disease process itself, but can
also earmark existing therapies to be investigated further as potential agents to be repurposed
to target dementia.
This study finds no evidence for concern about developing dementia after taking a PPI. This
may reassure people who are currently taking them, however due to the limitations of this study
further research is needed, for instance, to ascertain the effect of duration of PPI exposure.
Supporting information
S1 File.
(DOCX)
PLOS ONE Proton pump inhibitors and dementia risk in UK
PLOS ONE | https://doi.org/10.1371/journal.pone.0237676 September 18, 2020 9 / 12
Acknowledgments
This work was conducted as part of the Health Data Research–UK (HDRUK) project and the
National Centre for Population Health and Wellbeing Research (NCPHWR). Dr Roxanne
Cooksey had full access to all the data in the study and takes responsibility for the integrity of
the data and the accuracy of the data analysis. Dr Roxanne Cooksey, Swansea University, was
responsible for the data analysis of this project.
Author Contributions
Conceptualization: Roxanne Cooksey, Jonathan Kennedy, Michael S. Dennis, Valentina
Escott-Price, Ronan A. Lyons, Michael Seaborne, Sinead Brophy.
Data curation: Roxanne Cooksey, Jonathan Kennedy.
Formal analysis: Roxanne Cooksey, Michael S. Dennis, Valentina Escott-Price, Ronan A.
Lyons, Michael Seaborne, Sinead Brophy.
Investigation: Roxanne Cooksey, Jonathan Kennedy, Michael S. Dennis, Ronan A. Lyons,
Sinead Brophy.
Methodology: Roxanne Cooksey, Jonathan Kennedy, Valentina Escott-Price, Sinead Brophy.
Project administration: Roxanne Cooksey.
Resources: Roxanne Cooksey, Michael Seaborne.
Supervision: Roxanne Cooksey, Michael S. Dennis, Valentina Escott-Price, Ronan A. Lyons,
Michael Seaborne, Sinead Brophy.
Validation: Roxanne Cooksey.
Writing – original draft: Roxanne Cooksey, Jonathan Kennedy, Sinead Brophy.
Writing – review & editing: Roxanne Cooksey, Jonathan Kennedy, Michael S. Dennis, Valen-
tina Escott-Price, Ronan A. Lyons, Michael Seaborne, Sinead Brophy.
References
1. Katz PO, Gerson LB, Vela MF. Guidelines for the diagnosis and management of gastroesophageal
reflux disease. Am J Gastroenterol. 2013;
2. Cai S, GarcI´a RodrI´guez LA, MassO´ -GonzA´ lez EL, HernA´ ndez-DI´az S. Uncomplicated peptic ulcer in
the UK: Trends from 1997 to 2005. Aliment Pharmacol Ther. 2009;
3. Mazer-Amirshahi M, Mullins PM, Van Den Anker J, Meltzer A, Pines JM. Rising rates of proton pump
inhibitor prescribing in US emergency departments. Am J Emerg Med. 2014;
4. Lanas A, Chan FKL. Peptic ulcer disease. The Lancet. 2017.
5. Coxib and traditional NSAID Trialists’ Collaboration. Vascular and upper gastrointestinal effects of non-
steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.
Lancet. 382:769–79. https://doi.org/10.1016/S0140-6736(13)60900-9 PMID: 23726390
6. Lanas A. We are using too many PPIs, and we need to stop: A European perspective. American Journal
of Gastroenterology. 2016.
7. Pasina L, Nobili A, Tettamanti M, Salerno F, Corrao S, Marengoni A, et al. Prevalence and appropriate-
ness of drug prescriptions for peptic ulcer and gastro-esophageal reflux disease in a cohort of hospital-
ized elderly. Eur J Intern Med. 2011; https://doi.org/10.1016/j.ejim.2010.11.009 PMID: 21402255
8. Heidelbaugh JJ, Goldberg KL, Inadomi JM. Magnitude and economic effect of overuse of antisecretory
therapy in the ambulatory care setting. Am J Manag Care. 2010;
9. OECD.Stat. http://stats.oecd.org/Index.aspx?DataSetCode=HEALTH_PHMC. 21st June 2017 last day
accessed.
10. Forgacs I, Loganayagam A. Overprescribing proton pump inhibitors. BMJ. 2008.
PLOS ONE Proton pump inhibitors and dementia risk in UK
PLOS ONE | https://doi.org/10.1371/journal.pone.0237676 September 18, 2020 10 / 12
11. Tran-Duy A, Spaetgens B, Hoes AW, de Wit NJ, Stehouwer CDA. Use of Proton Pump Inhibitors and
Risks of Fundic Gland Polyps and Gastric Cancer: Systematic Review and Meta-analysis. Clinical
Gastroenterology and Hepatology. 2016.
12. Ahn JS, Eom CS, Jeon CY, Park SM. Acid suppressive drugs and gastric cancer: A meta-analysis of
observational studies. World J Gastroenterol. 2013;
13. Boardman HF, Delaney BC, Haag S. Partnership in optimizing management of reflux symptoms: A
treatment algorithm for over-the-counter proton-pump inhibitors. Current Medical Research and Opin-
ion. 2015. DOI: 10.1185/03007995.2015.1047745 PMID: 25950642
14. Bavishi C, DuPont HL. Systematic review: The use of proton pump inhibitors and increased susceptibil-
ity to enteric infection. Alimentary Pharmacology and Therapeutics. 2011.
15. Zacharioudakis IM, Zervou FN, Pliakos EE, Ziakas PD, Mylonakis E. Colonization with toxinogenic C.
difficile upon hospital admission, and risk of infection: A systematic review and meta-analysis. American
Journal of Gastroenterology. 2015.
16. Daniell HW. Acid suppressing therapy as a risk factor for Candida esophagitis. Dis Esophagus. 2016;
17. Leonard J, Marshall JK, Moayyedi P. Systematic review of the risk of enteric infection in patients taking
acid suppression. American Journal of Gastroenterology. 2007.
18. Tleyjeh IM, Bin Abdulhak AA, Riaz M, Alasmari FA, Garbati MA, AlGhamdi M, et al. Association
between Proton Pump Inhibitor Therapy and Clostridium difficile Infection: A Contemporary Systematic
Review and Meta-Analysis. PLoS ONE. 2012. DOI: 10.1371/journal.pone.0050836 PMID: 23236397
19. Lebwohl B, Spechler SJ, Wang TC, Green PHR, Ludvigsson JF. Use of proton pump inhibitors and sub-
sequent risk of celiac disease. Dig Liver Dis. 2014;
20. Jung SB, Nagaraja V, Kapur A, Eslick GD. Association between vitamin B12 deficiency and long-term
use of acid-lowering agents: A systematic review and meta-analysis. Intern Med J. 2015;
21. Sierra F, Suarez M, Rey M, Vela MF. Systematic review: Proton pump inhibitor-associated acute inter-
stitial nephritis. Alimentary Pharmacology and Therapeutics. 2007.
22. Moledina DG, Perazella MA. PPIs and kidney disease: from AIN to CKD. Journal of Nephrology. 2016.
23. Gomm W, Von Holt K, Thome´ F, Broich K, Maier W, Fink A, et al. Association of proton pump inhibitors
with risk of dementia: A pharmacoepidemiological claims data analysis. JAMA Neurol. 2016;
24. Haenisch B, von Holt K, Wiese B, Prokein J, Lange C, Ernst A, et al. Risk of dementia in elderly patients
with the use of proton pump inhibitors. Eur Arch Psychiatry Clin Neurosci. 2015;
25. Mattsson JP, Va¨a¨na¨nen K, Wallmark B, Lorentzon P. Omeprazole and bafilomycin, two proton pump
inhibitors: Differentiation of their effects on gastric, kidney and bone H+-translocating ATPases. BBA—
Biomembr. 1991;
26. Fallahzadeh MK, Borhani Haghighi A, Namazi MR. Proton pump inhibitors: Predisposers to Alzheimer
disease? Journal of Clinical Pharmacy and Therapeutics. 2010.
27. Lam JR, Schneider JL, Zhao W, Corley DA. Proton pump inhibitor and histamine 2 receptor antagonist
use and vitamin B12 deficiency. JAMA—J Am Med Assoc. 2013;
28. Booker A, Jacob LE, Rapp M, Bohlken J, Kostev K. Risk factors for dementia diagnosis in German pri-
mary care practices. Int Psychogeriatrics. 2016;
29. Wijarnpreecha K, Thongprayoon C, Panjawatanan P, Ungprasert P. Proton pump inhibitors and risk of
dementia. Ann Transl Med. 2016;
30. Goldstein FC, Steenland K, Zhao L, Wharton W, Levey AI, Hajjar I. Proton Pump Inhibitors and Risk of
Mild Cognitive Impairment and Dementia. J Am Geriatr Soc. 2017;
31. Taipale H, Tolppanen AM, Tiihonen M, Tanskanen A, Tiihonen J, Hartikainen S. No Association
Between Proton Pump Inhibitor Use and Risk of Alzheimer’s Disease. Am J Gastroenterol. 2017;
32. Lochhead P, Hagan K, Joshi AD, Khalili H, Nguyen LH, Grodstein F, et al. Association Between Proton
Pump Inhibitor Use and Cognitive Function in Women. Gastroenterology. 2017;
33. Song YQ, Li Y, Zhang SL, Gao J, Feng SY. Proton pump inhibitor use does not increase dementia and
Alzheimer’s disease risk: An updated meta-analysis of published studies involving 642305 patients.
PLoS One. 2019;
34. Li M, Luo Z, Yu S, Tang Z. Proton pump inhibitor use and risk of dementia: Systematic review and meta-
analysis. Medicine (United States). 2019.
35. Imfeld P, Bodmer M, Jick SS, Meier CR. Proton Pump Inhibitor Use and Risk of Developing Alzheimer’s
Disease or Vascular Dementia: A Case–Control Analysis. Drug Saf. 2018;
36. Savarino E, Marabotto E, Zentilin P, Furnari M, Bodini G, Pellegatta G, et al. A safety review of proton
pump inhibitors to treat acid-related digestive diseases. Expert Opinion on Drug Safety. 2018.
PLOS ONE Proton pump inhibitors and dementia risk in UK
PLOS ONE | https://doi.org/10.1371/journal.pone.0237676 September 18, 2020 11 / 12
37. Ford D V., Jones KH, Verplancke JP, Lyons RA, John G, Brown G, et al. The SAIL Databank: Building a
national architecture for e-health research and evaluation. BMC Health Serv Res. 2009;
38. Lyons RA, Jones KH, John G, Brooks CJ, Verplancke JP, Ford D V., et al. The SAIL databank: Linking
multiple health and social care datasets. BMC Med Inform Decis Mak. 2009;
39. Brophy S, Jones KH, Rahman MA, Zhou SM, John A, Atkinson MD, et al. Incidence of campylobacter
and salmonella infections following first prescription for PPI: A cohort study using routine data. Am J
Gastroenterol. 2013;
40. Chisholm J. The Read clinical classification. British Medical Journal. 1990.
41. Isolauri J, Laippala P. Prevalence of symptoms suggestive of gastroesophageal reflux disease in an
adult population. Ann Med. 1995;
42. Brown A, Kirichek O, Balkwill A, Reeves G, Beral V, Sudlow C, et al. Comparison of dementia recorded
in routinely collected hospital admission data in England with dementia recorded in primary care. Emerg
Themes Epidemiol. 2016;
43. Baroni L, Bonetto C, Rizzo G, Bertola C, Caberlotto L, Bazzerla G. Association between Cognitive
Impairment and Vitamin B12, Folate, and Homocysteine Status in Elderly Adults: A Retrospective
Study. J Alzheimer’s Dis. 2019;
44. Gottesman RF, Albert MS, Alonso A, Coker LH, Coresh J, Davis SM, et al. Associations between midlife
vascular risk factors and 25-year incident dementia in the Atherosclerosis Risk in Communities (ARIC)
cohort. JAMA Neurol. 2017;
45. Lystrup LS, Lillesveen B, Nygård A-M, Engedal K. [Public social health services to demented persons
living at home in Norway]. Tidsskr Nor Laegeforen. 2006;
46. Bradford A, Kunik ME, Schulz P, Williams SP, Singh H. Missed and delayed diagnosis of dementia in
primary care: Prevalence and contributing factors. Alzheimer Disease and Associated Disorders. 2009.
47. Gelman CR. Learning from recruitment challenges: Barriers to diagnosis, treatment, and research par-
ticipation for latinos with symptoms of Alzheimer’s Disease. J Gerontol Soc Work. 2010;
48. Schuemie MJ, Ryan PB, Man KKC, Wong ICK, Suchard MA, Hripcsak G. A plea to stop using the case-
control design in retrospective database studies. Stat Med. 2019;
49. Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of
competing risks: New representations of old estimators. Stat Med. 1999;
50. Satagopan JM, Ben-Porat L, Berwick M, Robson M, Kutler D, Auerbach AD. A note on competing risks
in survival data analysis. British Journal of Cancer. 2004.
51. Ortiz-Guerrero G, Amador-Muñoz D, Caldero´n-Ospina CA, Lo´pez-Fuentes D, Mesa MON. Proton
pump inhibitors and dementia: Physiopathological mechanisms and clinical consequences. Neural
Plasticity. 2018.
52. Sodhi RK, Singh N. Defensive Effect of Lansoprazole in Dementia of AD Type in Mice Exposed to
Streptozotocin and Cholesterol Enriched Diet. PLoS One. 2013;
PLOS ONE Proton pump inhibitors and dementia risk in UK
PLOS ONE | https://doi.org/10.1371/journal.pone.0237676 September 18, 2020 12 / 12
